Tokushima University / Educator and Researcher Directory --- Yamamoto, Takaaki

Search:

Tokushima University ⟩ Graduate School of Biomedical Sciences ⟩ 薬学域 ⟩ 先端薬学教育研究プロジェクト ⟩
Tokushima University ⟩ Graduate School of Biomedical Sciences ⟩ 薬学域 ⟩ Pharmaceutical Science ⟩ Pharmaceutical Educational Sciences ⟩ Department of Clinical pharmacy practice pedagogy ⟩
Tokushima University ⟩ Graduate School of Pharmaceutical Sciences ⟩ Pharmacy ⟩

(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

○	Clinical Pharmacy

Subject of Study

○	抗菌薬のtherapeutic drug monitoringに関する臨床研究

Book / Paper

Academic Paper (Judged Full Paper):

1.	T Tai, Takaaki Yamamoto, K Yamaguchi, M Watanabe, H Tanaka, Y Muraki and S Kosaka : Evaluation of the meropenem dosage and administration schedule in patients with bacteremia initial therapy., Journal of Infection and Chemotherapy, Vol.29, No.8, 749-753, 2023. (Summary) The standard meropenem (MEPM) regimen allowed by insurance in Japan is 0.5 g two or three times a day. Differences in dosages and administration schedules in Japan were evaluated. Patients with bacteremia for whom MEPM was used as the initial treatment at our institution between 2016 and 2021 were included. We retrospectively investigated patients classified into two groups: those treated according to severe infections (high-dose groupand others (low-dose group). After propensity score matching, we compared the probability of achieving free drug blood levels above the minimum inhibitory concentration (MIC) in 24 h (%fT > MIC) and outcomes. The probability of 100% fT > MIC was significantly higher in the high-dose group (96.4% vs 74.5%, odds ratio [OR] = 0.3, 95% confidence interval [CI] = 0.2-0.4, P = < 0.001). Regarding outcomes, the 30-day mortality rate was significantly lower in the high-dose group (1.4% vs. 11.4%, OR = 8.0, 95% CI = 1.5-43.7, P = 0.019). To improve outcomes in patients with bacteremia treated with MEPM, support for appropriate antimicrobial use is necessary for compliance with the dosage and administration schedule according to severe infections in initial treatment. (Keyword) Humans / Meropenem / Anti-Bacterial Agents / Retrospective Studies / Anti-Infective Agents / Bacteremia / Microbial Sensitivity Tests / Thienamycins (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jiac.2023.04.004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37086895 ● Search Scopus @ Elsevier (PMID): 37086895 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jiac.2023.04.004 (DOI: 10.1016/j.jiac.2023.04.004, PubMed: 37086895)

Proceeding of Domestic Conference:

1.	Yui Nagao, Chiemi Sato, YAMAKAWA Ayumi, Takaaki Yamamoto, Kei Kawada and Shinji Abe : ビタミンDサプリメントがアレルギー性鼻炎に与える効果の検討―システマティックレビューとメタ解析―, 日本薬学会第144年会(横浜), Mar. 2024.
2.	Wakako Minami, Chiemi Sato, Takaaki Yamamoto, Kei Kawada and Shinji Abe : 電子版お薬手帳の利用推進における問題点の検討―徳島県の薬局薬剤師に対するアンケート調査より―, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
3.	Chisaki Yamaguchi, Chiemi Sato, Yui Nagao, Takaaki Yamamoto, Kei Kawada and Shinji Abe : ベンゾジアゼピン受容体作動薬の服用と認知機能低下の関連性評価 ―システマティックレビューとメタ解析―, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
4.	Takuya Wada, Satoshi Itakura, Aito Yoshida, Takaaki Yamamoto, Kei Kawada, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗podoplanin抗体chLpMab-23fのMPM胸腔内移植マウスモデルにおける抗腫瘍効果の検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), Oct. 2023.
5.	Satoshi Itakura, Takuya Wada, Aito Yoshida, Takaaki Yamamoto, Kei Kawada, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗podoplanin抗体chLpMab-2及びコアフコース除去抗体chLpMab-2fのin vivoにおける抗腫瘍効果の検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), Oct. 2023.
6.	Aito Yoshida, Satoshi Itakura, Takuya Wada, Takaaki Yamamoto, Kei Kawada, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗podoplanin抗体のコアフコース除去に伴うADCC増強とNK細胞活性化に関する検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), Oct. 2023.